EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Beyond depletion: inositol as a candidate endocrine-metabolic countermeasure in psychotropic drug therapy

Cherubino Di Lorenzo, Giorgio Di Lorenzo

Frontiers in Psychiatry · 18.11.2026 · 17

DOI: 10.3389/fpsyt.2026.2033172 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Psychiatry, online erschienen am 18.11.2026. Verfasst von Cherubino Di Lorenzo und 1 weiteren Autor:innen. Die Arbeit nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inositol’s relevance to psychiatry has rested on the unresolved hypothesis that lithium acts through inositol depletion. Inositol could matter for patients treated with psychotropic drugs through two routes: a central route, which remains unresolved, and a peripheral route, in which inositol acts as an insulin-sensitizing agent and as a second messenger in thyroid and gonadal signaling. The peripheral evidence comes from populations without psychiatric illness, is of low certainty, and concerns surrogate measures, not incident diabetes or cardiovascular events. We examine four drug classes, antipsychotics, lithium, valproate, and antidepressants, each associated with weight gain and insulin resistance through partly distinct pathways, two of them also with thyroid or reproductive dysfunction, and grade the rationale in each. The rationale is strongest for olanzapine, which impairs the insulin-signaling node that inositol supports in rat muscle cells and induced weight-independent insulin resistance in a small study in healthy volunteers; this shows that the pathways converge, not that inositol would restore the impaired signaling. For lithium, the rationale is inseparable from the unresolved central mechanism, and a peripheral extension has not been measured. For valproate, reduced inositol synthesis is documented in yeast and mouse cells, while the peripheral finding in patients is reduced hepatic insulin clearance, not a defect at that node. For antidepressants, weight gain is common across the class, and impaired insulin sensitivity is reported mainly for select tricyclics. No controlled trial has tested inositol against psychotropic-induced endocrine and metabolic disruption; small, short trials with mood stabilizers detected no change in drug levels but were not powered for relapse or mood switch. We propose a prospective biomarker study that separates replacement of a depleted pool from a pharmacological effect; a placebo-controlled prevention trial at olanzapine initiation, with insulin sensitivity as the single primary endpoint, psychiatric outcomes monitored for safety, and a dose-finding phase comparing myo-inositol alone with combinations; and, as a complementary strategy, raising endogenous inositol synthesis. Because inositol is expected to be weight-neutral, no effect on adherence can be assumed. This synthesis is hypothesis-generating: we do not claim that inositol is protective, but identify an untested endocrine-metabolic rationale.

Zitieren

APA

Lorenzo, C. D., & Lorenzo, G. D. (2026). Beyond depletion: inositol as a candidate endocrine-metabolic countermeasure in psychotropic drug therapy. Frontiers in Psychiatry, 17. https://doi.org/10.3389/fpsyt.2026.2033172

Vancouver

Lorenzo CD, Lorenzo GD. Beyond depletion: inositol as a candidate endocrine-metabolic countermeasure in psychotropic drug therapy. Frontiers in Psychiatry. 2026;17. doi:10.3389/fpsyt.2026.2033172

BibTeX
@article{Lorenzo2026,
  author = {Lorenzo, Cherubino Di and Lorenzo, Giorgio Di},
  title = {Beyond depletion: inositol as a candidate endocrine-metabolic countermeasure in psychotropic drug therapy},
  journal = {Frontiers in Psychiatry},
  year = {2026},
  volume = {17},
  doi = {10.3389/fpsyt.2026.2033172}
}
Kostenlos starten →